Classification ![]() |
|
| Compound class | Peptide or derivative |
IUPAC Name ![]() |
| 2-[(2S,5R,8S,11S)-11-[3-(diaminomethylideneamino)propyl]-7-methyl-3,6,9,12,15-pentaoxo-5-(phenylmethyl)-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 7823 | cilengitide |
Synonyms ![]() |
| EMD-12192 |
| EMD-121974 |
Database Links ![]() |
|
| CAS Registry No. | 188968-51-6 |
| ChEMBL Ligand | CHEMBL429876 |
| PubChem CID | 176873 |
| Search Google for chemical match using the InChIKey | AMLYAMJWYAIXIA-VWNVYAMZSA-N |
| Search Google for chemicals with the same backbone | AMLYAMJWYAIXIA |
| Search PubMed clinical trials | cilengitide |
| Search PubMed titles | cilengitide |
| Search PubMed titles/abstracts | cilengitide |
| Wikipedia | Cilengitide |
| Comments |
| Cilengitide is a pentapeptide, first-in-class integrin inhibitor. It inhibits integrin αv-induced angiogenesis. It was investigated for anti-tumour activity. Glioblastoma was one of the cancers investigated [5], based on encouraging preclinical studies in animals [3-4,6]. |